Top Markets
Coin of the day
Stimcell Energetics, Inc. Stimcell Energetics, Inc.

Stimcell Energetics, Inc.

STME
株式のランク #34048
StimCell Energetics Inc. is a biotechnology company focused on the research,... StimCell Energetics Inc. is a biotechnology company focused on the research, development, and market introduction of both therapeutic and non-therapeutic solutions. These products are intended to benefit individuals in the United States who are managing conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and issues with kidney function. The company's primary product line is the eBalance system, which comprises two versions: the eBalance Pro System, designed for clinical application by healthcare practitioners, and the eBalance Home System, created for personal use to promote overall well-being and alleviate pain. Both systems are operated via the eBalance Console, a central control unit that offers three distinct pre-programmed microcurrent algorithms: one for general wellness, another for pain relief, and a 'dual' mode that combines both. Additionally, these eBalance products aim to provide temporary relief for discomfort in various body parts, including the shoulders, waist, back, neck, arms, and legs. Established in 2010, the company initially operated under the name Cell MedX Corp. before officially rebranding as StimCell Energetics Inc. in November 2024. Its corporate headquarters are located in Vancouver, Canada.
株価
$0.3
最終同期: 2026-08-13
時価総額
$6.34M
変化(1日)
0.00%
変化(1年)
5.26%
CA
取引 Stimcell Energetics, Inc. (STME)

カテゴリー

Stimcell Energetics, Inc.(STME)のP/E比率
2026 時点のP/E比率 TTM 0
Stimcell Energetics, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 0 です。2026 年末時点での P/E は 0 でした。
Stimcell Energetics, Inc. の P/E 比率の履歴(2026 〜 2026)
各年末のP/E比率
P/E比率 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差
35.77 -
US
34.86 -
US
21.39 -
IE
20.90 -
US
52.64 -
US
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。